Subarachnoid molecular hemoglobin after subarachnoid hemorrhage in rats: effect on the area of hypoperfusion.
A previous study indicated that diaspirin-crosslinked hemoglobin (DCLHb) decreases cerebral ischemia after subarachnoid hemorrhage. However, the study was limited in that DCLHb was given to animals with an intact vasculature. As extravasated hemoglobin has been implicated in the pathogenesis of cerebral vasospasm, DCLHb in the subarachnoid space might in theory have a detrimental effect on cerebral perfusion after subarachnoid hemorrhage. In the current study, autologous blood was administered into the cistema magna of isoflurane-anesthetized rats. After 30 minutes, the animals received one of the following in the cistema magna (n=8 for each group): The control group received mock cerebral spinal fluid, the "blood" group received autologous blood, the "DCLHb" group received DCLHb, and the "Alb" group received human serum albumin. After 20 minutes, areas of reduced cerebral blood flow (CBF, 0-20 and 21-40 ml/100 g/min) were assessed in five coronal brain sections with 14C-iodoantipyrine. The data were evaluated by analysis of variance. The areas of 0-20 ml/100 g/min CBF were greater in all five brain sections in the Blood group than in the other three groups; were greater in four brain sections in the DCLHb group than in the Control group; and were greater in three brain sections in the Alb group than in the Control group (p < 0.05). The areas of 21-40 ml/100 g/min CBF were greater in three sections in the Blood group than in the other three groups; and were greater in two brain sections in the DCLHb group than in the Alb group (p < 0.05). These data support a hypothesis that subarachnoid blood induces cerebral hypoperfusion, and that although molecular hemoglobin decreases CBF, the potential adverse effects are less than those produced by blood.
Cole
D J
DJ
Department of Anesthesiology, Loma Linda University, California 92354, USA.
McKay
L D
LD
Drummond
J C
JC
Patel
P M
PM
Cross
L M
LM
D000704:Analysis of Variance; D018685:Anesthetics, Inhalation / Q000008:administration & dosage; D000818:Animals; D000983:Antipyrine / Q000031:analogs & derivatives; D001241:Aspirin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001769:Blood; D001802:Blood Substitutes / Q000627:therapeutic use*; D001921:Brain / Q000000981:diagnostic imaging; D002545:Brain Ischemia / Q000503:physiopathology* / Q000517:prevention & control; D002250:Carbon Radioisotopes; D002555:Cerebrospinal Fluid; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D002946:Cisterna Magna; D005119:Extravasation of Diagnostic and Therapeutic Materials / Q000503:physiopathology; D006454:Hemoglobins / Q000627:therapeutic use*; D006801:Humans; D002546:Ischemic Attack, Transient / Q000209:etiology; D007530:Isoflurane / Q000008:administration & dosage; D008297:Male; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D051381:Rats; D011918:Rats, Inbred SHR; D012709:Serum Albumin / Q000627:therapeutic use; D013345:Subarachnoid Hemorrhage / Q000188:drug therapy*; D013346:Subarachnoid Space
D018685:Anesthetics, Inhalation; D001802:Blood Substitutes; D002250:Carbon Radioisotopes; D006454:Hemoglobins; D019275:Radiopharmaceuticals; D012709:Serum Albumin; D007530:Isoflurane; C083478:diaspirin-cross-linked hemoglobin; D001241:Aspirin; D000983:Antipyrine; C008135:iodoantipyrine